JP2014528901A5 - - Google Patents

Download PDF

Info

Publication number
JP2014528901A5
JP2014528901A5 JP2013557862A JP2013557862A JP2014528901A5 JP 2014528901 A5 JP2014528901 A5 JP 2014528901A5 JP 2013557862 A JP2013557862 A JP 2013557862A JP 2013557862 A JP2013557862 A JP 2013557862A JP 2014528901 A5 JP2014528901 A5 JP 2014528901A5
Authority
JP
Japan
Prior art keywords
deoxygalactonojirimycin
gal
administration
replacement therapy
enzyme replacement
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013557862A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014528901A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/028260 external-priority patent/WO2012125402A2/en
Publication of JP2014528901A publication Critical patent/JP2014528901A/ja
Publication of JP2014528901A5 publication Critical patent/JP2014528901A5/ja
Pending legal-status Critical Current

Links

JP2013557862A 2011-03-11 2012-03-08 ファブリー病の治療用投薬レジメン Pending JP2014528901A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201161451798P 2011-03-11 2011-03-11
US61/451,798 2011-03-11
US201161578201P 2011-12-20 2011-12-20
US61/578,201 2011-12-20
US201261596165P 2012-02-07 2012-02-07
US61/596,165 2012-02-07
PCT/US2012/028260 WO2012125402A2 (en) 2011-03-11 2012-03-08 Dosing regimens for the treatment of fabry disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017038469A Division JP2017132780A (ja) 2011-03-11 2017-03-01 ファブリー病の治療用投薬レジメン

Publications (2)

Publication Number Publication Date
JP2014528901A JP2014528901A (ja) 2014-10-30
JP2014528901A5 true JP2014528901A5 (cg-RX-API-DMAC7.html) 2015-04-30

Family

ID=46831259

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2013557862A Pending JP2014528901A (ja) 2011-03-11 2012-03-08 ファブリー病の治療用投薬レジメン
JP2017038469A Pending JP2017132780A (ja) 2011-03-11 2017-03-01 ファブリー病の治療用投薬レジメン
JP2019186952A Pending JP2020033360A (ja) 2011-03-11 2019-10-10 ファブリー病の治療用投薬レジメン
JP2021018456A Withdrawn JP2021098697A (ja) 2011-03-11 2021-02-08 ファブリー病の治療用投薬レジメン
JP2023045001A Pending JP2023093448A (ja) 2011-03-11 2023-03-22 ファブリー病の治療用投薬レジメン

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2017038469A Pending JP2017132780A (ja) 2011-03-11 2017-03-01 ファブリー病の治療用投薬レジメン
JP2019186952A Pending JP2020033360A (ja) 2011-03-11 2019-10-10 ファブリー病の治療用投薬レジメン
JP2021018456A Withdrawn JP2021098697A (ja) 2011-03-11 2021-02-08 ファブリー病の治療用投薬レジメン
JP2023045001A Pending JP2023093448A (ja) 2011-03-11 2023-03-22 ファブリー病の治療用投薬レジメン

Country Status (16)

Country Link
US (4) US20140219986A1 (cg-RX-API-DMAC7.html)
EP (2) EP2683382B1 (cg-RX-API-DMAC7.html)
JP (5) JP2014528901A (cg-RX-API-DMAC7.html)
KR (1) KR20140011367A (cg-RX-API-DMAC7.html)
CN (2) CN107088225A (cg-RX-API-DMAC7.html)
AU (6) AU2012229330B2 (cg-RX-API-DMAC7.html)
CA (1) CA2829947C (cg-RX-API-DMAC7.html)
CL (1) CL2013002601A1 (cg-RX-API-DMAC7.html)
EA (1) EA031874B1 (cg-RX-API-DMAC7.html)
ES (1) ES2807502T3 (cg-RX-API-DMAC7.html)
HK (1) HK1242998A1 (cg-RX-API-DMAC7.html)
MX (1) MX2013010446A (cg-RX-API-DMAC7.html)
SG (2) SG10201604757RA (cg-RX-API-DMAC7.html)
TW (3) TW201740945A (cg-RX-API-DMAC7.html)
WO (1) WO2012125402A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA201306735B (cg-RX-API-DMAC7.html)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2533050T6 (da) 2006-05-16 2015-09-21 Amicus Therapeutics Inc Behandlingsmuligheder ved Fabrys sygdom
HUE042882T2 (hu) 2008-02-12 2019-07-29 Amicus Therapeutics Inc Eljárás betegségek farmakológiai chaperonnal történõ kezelésére adott válasz elõrejelzésére
UY34317A (es) 2011-09-12 2013-02-28 Genzyme Corp Anticuerpo antireceptor de célula T (alfa)/ß
US9790268B2 (en) 2012-09-12 2017-10-17 Genzyme Corporation Fc containing polypeptides with altered glycosylation and reduced effector function
WO2014164534A2 (en) 2013-03-11 2014-10-09 Genzyme Corporation Site-specific antibody-drug conjugation through glycoengineering
CN106687596A (zh) * 2014-02-17 2017-05-17 葛兰素史密斯克莱知识产权发展有限公司 微生物学方法
RS64072B1 (sr) 2014-03-19 2023-04-28 Genzyme Corp Mesto-specifični glikoinženjering ciljnih delova
US9675627B2 (en) * 2014-04-14 2017-06-13 Amicus Therapeutics, Inc. Dosing regimens for treating and/or preventing cerebral amyloidoses
GB201508025D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Fabry disease gene therapy
JP7001593B2 (ja) 2015-08-11 2022-01-19 コグノア, インコーポレイテッド 人工知能およびユーザ入力を用いて発達進度を判定するための方法および装置
US11972336B2 (en) 2015-12-18 2024-04-30 Cognoa, Inc. Machine learning platform and system for data analysis
EP3432882B1 (en) * 2016-03-22 2021-09-01 Amicus Therapeutics, Inc. Methods of treating fabry disease in patients having the g9331a mutation in the gla gene
KR20240017126A (ko) * 2016-07-19 2024-02-06 아미쿠스 세라퓨틱스, 인코포레이티드 Ert-치료경험이 없는 환자 및 있는 환자에서 파브리병의 치료
WO2018090009A1 (en) 2016-11-14 2018-05-17 Cognoa, Inc. Methods and apparatus for evaluating developmental conditions and providing control over coverage and reliability
JP7324709B2 (ja) * 2017-02-09 2023-08-10 コグノア,インク. デジタル個別化医療のためのプラットフォームとシステム
HUE069837T2 (hu) * 2017-05-30 2025-04-28 Amicus Therapeutics Inc Bizonyos mutációkat hordozó Fabry-kóros betegek kezelése
BR112019025083B1 (pt) 2017-05-30 2022-08-09 Amicus Therapeutics, Inc Métodos de tratamento de pacientes portadores de fabry com insuficiência renal
JP7066157B2 (ja) 2017-06-14 2022-05-13 学校法人 明治薬科大学 ファブリー病治療用医薬の組合せ物及びその利用
EP3749307B1 (en) * 2018-02-06 2025-12-10 Amicus Therapeutics, Inc. Use of migalastat for treating fabry disease in pregnant patients
EP4299117A3 (en) * 2018-08-20 2024-02-21 Amicus Therapeutics, Inc. Methods of treating fabry disease in patients having a mutation in the gla gene
AU2020248351B2 (en) 2019-03-22 2025-09-25 Cognoa, Inc. Personalized digital therapy methods and devices
CN113939534B (zh) 2019-04-03 2025-02-28 建新公司 具有降低的断裂的抗αβTCR结合多肽
EA202290024A1 (ru) * 2019-06-11 2022-03-14 Амикус Терапьютикс, Инк. Способы лечения болезни фабри у пациентов с почечной недостаточностью
CA3147055A1 (en) 2019-08-07 2021-02-11 Elfrida Benjamin Methods of treating fabry disease in patients having a mutation in the gla gene
US11623916B2 (en) 2020-12-16 2023-04-11 Amicus Therapeutics, Inc. Highly purified batches of pharmaceutical grade migalastat and methods of producing the same
US20240120050A1 (en) * 2022-10-07 2024-04-11 Insight Direct Usa, Inc. Machine learning method for predicting a health outcome of a patient using video and audio analytics
US20240197706A1 (en) * 2022-12-13 2024-06-20 Amicus Therapeutics, Inc. Methods of improving the pharmacokinetics of migalastat

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4551177A (en) * 1984-04-23 1985-11-05 National Starch And Chemical Corporation Compressible starches as binders for tablets or capsules
US6274597B1 (en) * 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
ES2686775T3 (es) * 2003-01-31 2018-10-19 Mount Sinai School Of Medicine Of New York University Terapia de combinación para tratar trastornos de deficiencia de proteínas
US7879354B2 (en) * 2004-01-13 2011-02-01 Mcneil-Ppc, Inc. Rapidly disintegrating gelatinous coated tablets
CN100457106C (zh) * 2005-06-15 2009-02-04 同济大学 1-脱氧野尻霉素在制备治疗糖尿病肾病药物中的应用
DK2533050T6 (da) * 2006-05-16 2015-09-21 Amicus Therapeutics Inc Behandlingsmuligheder ved Fabrys sygdom
US20100113517A1 (en) * 2007-03-30 2010-05-06 Amicus Therapeutics, Inc. Method for the treatment of fabry disease using pharmacological chaperones
US9056101B2 (en) * 2007-04-26 2015-06-16 Amicus Therapeutics, Inc. Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
US20100291060A1 (en) * 2007-08-29 2010-11-18 Shire Human Genetic Therapies, Inc Subcutaneous administration of alpha-galactosidase a

Similar Documents

Publication Publication Date Title
JP2014528901A5 (cg-RX-API-DMAC7.html)
JP2020033360A5 (cg-RX-API-DMAC7.html)
JP2015519329A5 (cg-RX-API-DMAC7.html)
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
WO2014205229A8 (en) Use of high dose pridopidine for treating huntington's disease
EA201270144A1 (ru) Комбинированная терапия при лечении диабета
PE20142319A1 (es) Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero
JP2014515373A5 (cg-RX-API-DMAC7.html)
WO2012007159A3 (en) Novel gastro-retentive dosage forms
JP2015524444A5 (cg-RX-API-DMAC7.html)
AR090885A1 (es) Uso de laquinimod en alta dosis para el tratamiento de la esclerosis multiple
RU2010107843A (ru) Бупропиона гидробромид и его терапевтические применения
JP2013509411A5 (cg-RX-API-DMAC7.html)
RU2015134581A (ru) Доноры нитроксила с улучшенным терапевтическим индексом
JP2013541583A5 (cg-RX-API-DMAC7.html)
JP2015532293A5 (ja) 糖尿病患者における心不全の治療用組成物
RU2012108656A (ru) Применение 4-аминопиридина для улучшения состояния при нейрокогнитивном и/или нейропсихиатрическом нарушении у пациентов с демиелинизирующими и другими заболеваниями нервной системы
JP2017526693A5 (cg-RX-API-DMAC7.html)
JP2016505050A5 (cg-RX-API-DMAC7.html)
RU2013112890A (ru) Терапевтическое применение 1-[2-(2,4-диметилфенилсульфанил)фенил]пиперазина
JP2015512948A5 (cg-RX-API-DMAC7.html)
JP2019535830A5 (cg-RX-API-DMAC7.html)
TN2016000179A1 (en) Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor.
JP2015524460A5 (cg-RX-API-DMAC7.html)
RU2012122649A (ru) Способ диагностики ишемии миокарда у больных кардиальным синдромом х